Viscient Biosciences » Healthcare 3D Printing Bioprinting Directory

Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

 

Organization Name
Categories
Headquater location
Description

Viscient Biosciences

Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to discover and develop drugs across a range of therapeutic areas with significant unmet medical need.

Headquarters Bld 2, rm 148, 3550 General Atomics Ct San Diego CA 92121 United States
  • blank
Categories: Bioprinting
Links:

Details

Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to discover and develop drugs across a range of therapeutic areas with significant unmet medical need.

By leveraging our expertise in complex, three-dimensional disease models comprised of human cells and complex analytical methods, we are able to drive drug discovery in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients’ lives.  The traditional reliance on animal models of disease today often leads to clinical trial failures due to species differences that prevent accurately reproducing human disease. Viscient is creating a more faithful picture of specific human diseases by relying on human cells and a 3D reconstruction of the tissue to show the truest possible biology in vitro.  Then, our expertise in transcriptomics and other methods allows us to detect genes and pathways that drive disease progression.  These driver genes are critical targets for our drug discovery programs.

We are initially conducting discovery and development work in non-alcoholic steatohepatitis (NASH), an area expected to have future drug revenue for pharma of up to $40B per year.  We have achieved disease progression in vitro, identified novel disease-driver gene targets and are moving to build medicinal chemistry to develop drugs that modulate these targets.